Press Releases May 12, 2026 04:05 PM

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

Neumora Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
NMRA

Neumora Therapeutics, a clinical-stage biopharmaceutical company focusing on novel neuroscience drug development, announced it will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The event will be webcast live and archived for up to 30 days.

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
NMRA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Neumora specializes in developing therapies targeting novel mechanisms for brain diseases addressing underserved, prevalent conditions.
  • The company will present at a major healthcare investment conference, providing exposure to investors and stakeholders.
  • A live webcast and replay will be available, enhancing visibility and investor engagement.

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 1:35 p.m. ET.

A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Neumora Contact:
Helen Rubinstein
617-402-5700
[email protected]


Risks

  • Clinical-stage status means therapies are in development and subject to regulatory and clinical trial risks, which could delay or prevent product approval.
  • Market reception depends on the company's ability to advance its pipeline successfully in a competitive biopharmaceutical sector.
  • Uncertainties related to the evolving healthcare regulations and reimbursement environment may impact future commercialization.

More from Press Releases

Space Exploration Technologies Corporation to Join the Nasdaq-100 Index® Beginning July 7, 2026 Jun 26, 2026 XMax Announces Up to Approximately US$25 million in AI API-Related Service Contracts and Expansion into GPU-as-a-Service Jun 26, 2026 Cartesian Growth Corporation IV Announces Closing of $275 Million Initial Public Offering Jun 26, 2026 dLocal added to membership of US small-cap Russell 2000® Index Jun 26, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Jun 26, 2026